Panel Discussion | Advanced Heart Failure Therapies: Focus on Cardiac Transplantation

Saturday, March 7, 2026

11:47 AM - 12:05 PM EST

Location: Georgetown

Moderator(s)

Samer Najjar, MD

Regional Chief of Cardiology (Baltimore)
MedStar Health
Baltimore, Maryland, United States

Disclosure information not submitted.
MR

Mark Russo, MD

Disclosure information not submitted.
Matthew Sherwood, MD, MHS

System Director of Interventional Cardiology, Director of Structural Heart Program
Inova Schar Heart and Vascular Institute, Virginia, United States

Disclosure information not submitted.

Panel Discussant(s)

Waleed Al-Darzi, MD

Advanced Heart Failure and Transplant Cardiologist. Clinical Assistant Professor, Department of Medicine at Michigan State University
Henry Ford Health
Detroit, Michigan, United States

Disclosure(s): No financial relationships to disclose
KB

Keki Balsara, MD, MBA, FACS, FACC

Surgical Director, Heart Transplantation and Mechanical Circulatory Support
Medstar Health

Disclosure information not submitted.
Richa Gupta, MD

Assistant Professor of Medicine, Advanced Heart Failure and Transplant Cardiology
MedStar Health

Disclosure information not submitted.
Jean-Michel Paradis, MD

Structural and Interventional Cardiologist
Quebec Heart and Lung Institute
Quebec, Quebec, Canada

Disclosure(s): No financial relationships to disclose
Sean P. Pinney, MD

Chief of Cardiology, Mount Sinai Morningside
Icahn School Of Medicine At Mount Sinai Morningside/West
New York, New York, United States

Disclosure information not submitted.
Ryan J. Tedford, MD

Chief, Heart Failure; Peter C. Gazes Chair in Heart Failure
Medical University of South Carolina, South Carolina, United States

Disclosure(s): 35Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing); Abiomed: travel reimbursement (Terminated, February 9, 2026); Acorai: Consulting Fees (e.g., advisory boards) (Ongoing); Adona: Consulting Fees (e.g., advisory boards) (Ongoing); Aria CV: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); CVRx: Travel to meeting (Terminated, February 9, 2026); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Ongoing); Endotronix: Consulting Fees (e.g., advisory boards) (Ongoing); Fauna Bio: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Gradient: Consulting Fees (e.g., advisory boards) (Ongoing); Imbria: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Morphic: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Pulmonvant: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Restore Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Tempus AI: Consulting Fees (e.g., advisory boards) (Ongoing); United Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)
Melana Yuzefpolskaya, MD

Associate Professor of Medicine
Columbia Presbyterian Medical Center, New York, United States

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Waleed Al-Darzi, MD: No financial relationships to disclose

Jean-Michel Paradis, MD: No financial relationships to disclose

Ryan Tedford, MD: 35Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing); Abiomed: travel reimbursement (Terminated, February 9, 2026); Acorai: Consulting Fees (e.g., advisory boards) (Ongoing); Adona: Consulting Fees (e.g., advisory boards) (Ongoing); Aria CV: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); CVRx: Travel to meeting (Terminated, February 9, 2026); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Ongoing); Endotronix: Consulting Fees (e.g., advisory boards) (Ongoing); Fauna Bio: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Gradient: Consulting Fees (e.g., advisory boards) (Ongoing); Imbria: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Morphic: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Pulmonvant: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Restore Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Tempus AI: Consulting Fees (e.g., advisory boards) (Ongoing); United Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)

Melana Yuzefpolskaya, MD: No financial relationships to disclose